Saturday, June 15, 2024

Neurological Diseases: Ipsen and Skyhawk Therapeutics Announce RNA-Targeting Research Collaboration

Similar articles

Neurological diseases are the focus of a groundbreaking collaboration between Ipsen and Skyhawk Therapeutics to discover and develop novel small molecules that modulate RNA for the treatment of rare neurological conditions. The agreement includes an option for Ipsen to acquire exclusive global rights to two promising candidates developed under this collaboration. Once these development candidates (DCs) are validated, Ipsen will take on the responsibility for further development and commercialization, leveraging its extensive neuroscience expertise, particularly in movement disorders.

The agreement includes an option for Ipsen to acquire exclusive global rights to two promising candidates developed under this collaboration. Once these development candidates (DCs) are validated, Ipsen will take on the responsibility for further development and commercialization, leveraging its extensive neuroscience expertise, particularly in movement disorders.

Exclusive Global Rights: Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration. This strategic move allows Ipsen to enhance its portfolio with innovative treatments for rare neurological diseases.

Development and Commercialization: Following successful DC nomination, Ipsen will assume responsibility for all subsequent development and commercialization activities. This includes utilizing their existing neuroscience expertise, particularly in movement disorders, to bring these novel therapies to market.

Skyhawk’s Platform Technology: Skyhawk Therapeutics has developed a promising platform technology that enables the exploration of previously undruggable RNA targets with small molecules. This technology significantly expands the landscape of potential disease targets, offering new avenues for therapeutic intervention in rare neurological diseases.

Steve Glyman, SVP and Head of Neuroscience, Research & Development at Ipsen, expressed his enthusiasm about the collaboration: “We are delighted to join forces with the expert teams at Skyhawk, as we explore the potential for modifying RNA expression across rare and debilitating neurological conditions. Our focus and expertise in movement disorders, and across our portfolio, is bringing best and first-in-class treatments to those with the highest unmet needs, now further fueled by this novel platform at the cutting-edge of research.”

Sergey Paushkin, Chief Scientific Officer at Skyhawk, highlighted the shared mission and potential impact of the partnership: “Ipsen is an extraordinary company with a deep passion for serving patients, and we are excited to partner with them to expand their pipeline of innovative therapies. Our strategic partnership underscores our shared ambition to develop transformative medicines for people with rare neurological diseases for which there are no approved therapeutics.”

Neurological Diseases

Neurological Diseases: Skyhawk Eligible for Up to $1.8 Billion in Milestones Under Ipsen Collaboration

Under the terms of the agreement, Skyhawk is eligible to receive up to $1.8 billion in development, regulatory, and commercial milestones. This includes an upfront payment for the option and research collaboration, along with the potential for tiered royalties. This substantial financial commitment reflects the high potential and significant impact expected from this collaboration.

You can follow our news on our Telegram and LinkedIn accounts.

The collaboration leverages Skyhawk’s unique platform technology, which accelerates the development of RNA-targeting small molecules across various therapeutic areas, including rare neurological diseases. This platform allows for the identification and targeting of previously undruggable RNA sequences, opening up new possibilities for treating conditions that currently have no approved therapeutics.

The collaboration between Ipsen and Skyhawk represents a significant advancement in the field of RNA-targeting therapies. By combining Skyhawk’s innovative platform with Ipsen’s deep expertise in neuroscience and movement disorders, the partnership aims to develop first-in-class and best-in-class treatments for rare neurological diseases. This collaboration is poised to bring new hope to patients with these conditions, addressing unmet medical needs and improving their quality of life.

As the development candidates progress through the pipeline, the collaboration will focus on ensuring rigorous validation and swift development to bring these therapies to patients as quickly as possible. The shared commitment to innovation and patient care underpins the partnership, promising transformative advancements in the treatment of rare neurological diseases.

In conclusion, the collaboration between Ipsen and Skyhawk Therapeutics marks a major milestone in the pursuit of effective treatments for rare neurological diseases. With the potential to deliver groundbreaking therapies and significantly improve patient outcomes, this partnership exemplifies the power of strategic collaboration in advancing medical research and therapeutic development.

Resource: İpsen, April 22, 2024

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article